Somatic mutations in human cancer: applications in molecular epidemiology.

[1]  H. Whittle,et al.  Ser‐249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa , 2004, International journal of cancer.

[2]  T. Kunkel.  DNA Replication Fidelity* , 2004, Journal of Biological Chemistry.

[3]  D. Choubey,et al.  Resistance to UV‐induced apoptosis in human keratinocytes during accelerated senescence is associated with functional inactivation of p53 , 2004, Journal of cellular physiology.

[4]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[5]  Jürgen Geisler,et al.  TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Hanawalt,et al.  Functional characterization of global genomic DNA repair and its implications for cancer. , 2003, Mutation research.

[7]  L. Donehower,et al.  Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis , 2003, Oncogene.

[8]  Paul T Strickland,et al.  Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. , 2003, Carcinogenesis.

[9]  P. Hainaut,et al.  Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. , 2003, The Journal of thoracic and cardiovascular surgery.

[10]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[11]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[12]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[13]  J. Essigmann,et al.  The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Hainaut,et al.  Genotoxic and non-genotoxic pathways of p53 induction. , 2001, Cancer Letters.

[15]  Yaolin Wang,et al.  Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210 , 2001, The Journal of Biological Chemistry.

[16]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[17]  J. Essigmann,et al.  The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. , 2001, Carcinogenesis.

[18]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[19]  P. Hainaut,et al.  New approaches to understanding p53 gene tumor mutation spectra. , 1999, Mutation research.

[20]  P. May,et al.  Twenty years of p53 research: structural and functional aspects of the p53 protein , 1999, Oncogene.

[21]  D. Bell,et al.  XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.

[22]  G. Capellá,et al.  p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Harris,et al.  Hepatitis B virus X protein inhibits nucleotide excision repair , 1999, International journal of cancer.

[24]  A. Riggs,et al.  The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts , 1998, Oncogene.

[25]  C. Potten,et al.  Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. , 1998, The American journal of pathology.

[26]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[27]  A. Børresen-Dale,et al.  Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. , 1998, British Journal of Cancer.

[28]  K. McLure,et al.  How p53 binds DNA as a tetramer , 1998, The EMBO journal.

[29]  L. Mullenders,et al.  Transcription coupled repair and its impact on mutagenesis. , 1998, Mutation research.

[30]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[31]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[32]  C. Harris,et al.  Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. , 1997, Carcinogenesis.

[33]  G. Wahl,et al.  p53 Mediates Permanent Arrest over Multiple Cell Cycles in Response to γ-Irradiation , 1997 .

[34]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[35]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[36]  J. Essigmann,et al.  The relationship between the chemical structures and mutagenic specificities of the DNA lesions formed by chemical and physical mutagens. , 1993, Toxicology letters.

[37]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[38]  A. Puisieux,et al.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.

[39]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[40]  H. Mulcahy,et al.  Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients , 2004, Cancer and Metastasis Reviews.

[41]  M. Kastan,et al.  ATM--a key determinant of multiple cellular responses to irradiation. , 2001, Acta oncologica.

[42]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[43]  P. Hainaut,et al.  Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[44]  A. Børresen-Dale,et al.  TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  P. Hainaut,et al.  The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models. , 1997, IARC scientific publications.

[46]  Stylianos E. Antonarakis,et al.  The nature and mechanisms of human gene mutation , 1995 .

[47]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.